Biotech Values

[xavierprivas]

Two things to consider

On their Top-line Data (two first bullet items in PR):

- The median change in 28-day seizure frequency from baseline in the ITT (intent-to-treat) population (primary endpoint) was a decrease of 43% (n=7).
- The median change from baseline in seizure-free days in the ITT population (key secondary endpoint) was an increase of 78% (n=5; two subjects cannot be calculated due to 0 baseline seizure-free days).

The sample size is too small n=7 and they play fast and loose with the ITT
(switching from n=7 in 1st bullet item to n=5 in 2nd bullet).

On the other hand
Ecor1 acquired 12.2% MRNS (reported 8/8/17 in Edgar)
Deerfield acquired 9.98% MRNS (reported 7/17/17 in Edgar)

FWIW I sold all my position on MRNS